G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Associate Director - Biostatistics

Full-Time
$177.9k - $253.2k+ Discretionary annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PharmD, PhD
Foster City, CA, USA+1 moreMore locations: Parsippany-Troy Hills, NJ, USA
Hybrid
Biology & BiotechQuantitative Biology & Biostatistics
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A Bachelor's degree and 10 years of experience, or a Master's degree and 8 years of experience, or a PhD or PharmD and 5 years of experience.
  • Knowledge of biomedical statistical analysis, including independence in designing, implementing, and managing multiple statistical analysis strategies, plans, deliverables, and resource management.
  • Knowledge of biostatistics best practices and tools, with the ability to apply them to improve results.
  • Understanding of drug development phases and associated clinical trials across phases.
  • Knowledge of FDA and EMA regulations, ICH guidelines, and GCP, plus familiarity with standard clinical procedures.
Responsibilities
  • Provide strategic and operational statistical leadership for clinical development programs in the Virology Therapeutic Area.
  • Serve as lead statistician for Phase 1–3 clinical trials, with responsibility for overall statistical strategy and delivery.
  • Act as biostatistics lead on clinical studies or other non-molecule projects.
  • Represent Biostatistics on study management teams and development teams, providing strategic statistical leadership and collaborating with Biostatistics colleagues and cross-functional teams.
  • Provide statistical consultation on trial design, endpoints, and analysis methods, and author statistical analysis plans.
  • Oversee and lead technical and operational statistical activities for a group of clinical trials; direct internal and external teams in defining, executing, and completing statistical activities for one or more molecules or marketed products.
  • Contribute strategic statistical leadership to cross-functional clinical development planning and protocol development.
  • Advise internal and external partners, where applicable, on statistical analysis strategies, reliability of measurements, identifiability of models, and interpretation and presentation of statistical results.
  • Review and analyze safety reporting, biomarker analyses, and other aspects of clinical trial monitoring to inform development decisions.
  • Use advanced statistical software, methods, and techniques to gather, analyze, and interpret historical and external data for clinical development.
  • Provide biostatistical input into clinical development documentation, scientific publications and presentations, and regulatory documentation.
  • Participate in or lead special projects benefiting multiple Biostatistics team members, including innovative methodologies, processes, technology, and tools; participate in developing or implementing standard operating procedures and related documentation.
  • Adhere to regulatory requirements of study conduct, statistical analysis principles, industry standards, and Gilead standard operating procedures.
  • Create an inclusive team environment and embed the value of diversity in team management.
  • Develop employees by understanding their skills, experience, aspirations, and potential, and coaching them on performance and growth.
  • Empower teams by aligning goals and organizational objectives, holding teams accountable, removing barriers, and connecting teams to the broader organization.
Desired Qualifications
  • Demonstrated ability to rapidly assimilate scientific and statistical information.
  • Ability to adapt to change, move between projects, and provide support or expertise where needed.
  • Ability to think strategically when advising others on statistical requirements and opportunities to improve study or project outcomes.
  • Strong written and verbal communication, collaboration, and organizational skills.
  • Experience in HBV and HIV programs.
  • Familiarity with innovative trial designs.
  • Effectiveness managing projects and teams.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid family time off and paid parental time off
  • Generous 401(k) contribution matching
  • Comprehensive medical plans that cover both physical and mental healthcare
  • Global Wellbeing Reimbursement
  • Time Off
  • Global Volunteer Day
  • Giving Together Program
  • Employee Support Programs
  • Flexible Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 27th, 2026
ETFs sell net $30.4M of Gilead Sciences as AVLV exits $28.3M position

ETFs sold a net $30.4 million of Gilead Sciences (GILD) on Friday, October 23, extending a four-day selling streak. AVLV drove the activity, cutting $28.3 million and leaving it with no shares. More funds bought than sold, with 29 ETFs adding shares and 14 cutting them, but the sellers moved larger amounts. SPY trimmed $10.5 million and XLV sold $7.5 million. Net selling was $2.8 million on October 22, $17.0 million on October 21, and $19.3 million on October 20. ETFs had bought a net $58.2 million on October 19. Gilead has a market cap of $196.8 billion. Trailing 12-month revenue was $30.54 billion, up 6.5% over one year, and the shares have returned 31.62% this year.

Yahoo Finance
Oct 26th, 2026
Biktarvy growth halves to 7% as it drives 48.7% of Gilead's sales

Gilead Sciences' HIV drug Biktarvy is growing more slowly, raising questions about the company's reliance on it. Sales rose 6.8% in fiscal 2025, down from 13.3% a year earlier, and reached $3.8 billion in the second quarter of 2026, up 7%. Biktarvy made up 48.7% of fiscal 2025 revenue. It added about $0.9 billion in sales that year, more than the roughly $0.7 billion by which total revenue grew. Management expects the HIV treatment market to return to annual growth of 2% to 3%. Prevention sales doubled in the second quarter, topping $1 billion for the first time, and Gilead now expects full-year HIV sales to grow 9% to 10%, up from 8%. Gilead trades at 6.4 times sales, against 3.2 for the S&P 500.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Pharmaceutical Technology
Oct 23rd, 2026
Gilead spends $1.28bn on PepStar's potential Icotyde rival.

Gilead spends $1.28bn on PepStar's potential Icotyde rival. Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast. Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 receptor inhibitor, which the company hopes will rival Johnson & Johnson's recently approved therapy Icotyde (icotrokinra). Through this deal, Gilead will hand over $1.275bn upfront to obtain the rights to PepStar's macrocyclic peptide IL-23R inhibitor pill programme. This includes its lead asset, HCXT-2001, which is currently in Phase I trials. While the IL-23R inhibitor class has thus far made its commercial mark in plaque psoriasis, clinical success is now being seen in inflammatory bowel disease (IBD). Gilead is prioritising the latter with HCXT-2001, though the company is yet to specify which specific indications it will pursue. Unlike other options on the market, HCXT-2001 has an extended half-life, leading Gilead's CMO, Dietmar Berger to claim that the drug could offer a "potentially differentiated approach" to the company's burgeoning inflammation pipeline - which is primarily focused on IBD, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune diseases. "We see potential for HCXT-2001 alone or in combination, including with emvistegrast, as a daily oral treatment for people living with IBD," Berger added. Emvistegrast is Gilead's in-house developed α4β7 integrin inhibitor, which is currently in mid-stage development for IBD. The drug has already demonstrated its potential, having recently met its primary endpoint in patients with ulcerative colitis (UC) during the Phase II SWIFT study (NCT06290934). According to Jefferies analysts, this deal is a good move from Gilead as it allows the company to pursue a promising combination. "Proof of concept data from ABBV-266 [a combination of risankizumab and trosunilimab] shows that a4b7 + IL-23 may offer the best clinical remission in patients with prior advanced treatment," they commented. Meanwhile, they add that preclinical pharmacokinetic studies have pointed toward the early favourability of HCXT-2001 versus Icotyde - pointing to early signs of the drug's differentiated potential. Gilead doubles down on dealmaking. Gilead's deal with PepStar is the latest in a string of deals inked by the California-based pharma, which is currently preparing itself for several key patent expiries across its virology portfolio. To bolster its pipeline and bring new promising assets in, Gilead has inked three acquisitions in 2026. This includes its $7.8bn buyout of CAR-T specialist, Arcellx, as well as its takeovers worth up to $5bn and $2.2bn of antibody-drug conjugate (ADC) developer Tubulis and autoimmune T-cell engager (TCE) therapy-focused biotech Ouro Medicines, respectively. In the same vein, Gilead also recently forged a $1.9bn licensing pact with Vir Biotechnologies centred around next-generation TCEs for solid tumours. According to a recent report by GlobalData, parent company of Pharmaceutical Technology, more than half of the 157 surveyed pharmaceutical professionals feel optimistic or very optimistic about industry growth within the next 12 months. Give your business an edge with its leading industry insights.